Invalidity dossier
US 5661130
Absorption enhancers for drug administration
Current assignee: UAB Research Foundation
Added 9/23/2026, 6:29:11 PM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview: US5661130A — "Absorption Enhancers for Drug Administration"
Bibliographic data (as supplied): US Patent 5,661,130A; application US08/083,074; filed 1993-06-24; priority date 1993-06-24 (assumption noted in source); granted/publication date 1997-08-26; inventors Elias Meezan and Dennis J. Pillion; original and current assignee UAB Research Foundation; status listed as "Expired – Lifetime" (anticipated expiration 2014-08-26). Related filings noted: AU71777/94A and PCT/US1994/007123 (WO1995000151A1).
Purpose: The invention concerns increasing absorption of compounds into the circulatory system via the ocular, nasal, nasolacrimal, or inhalation routes, and specifically raising or lowering blood glucose using glucagon or insulin, respectively.
Plain-language scope (from the supplied text): The method administers a compound together with an absorption-increasing amount of a nontoxic, nonionic alkyl glycoside—a hydrophobic alkyl joined by a linkage to a hydrophilic saccharide. Compound and alkyl glycoside may be mixed before administration (preferred) or given sequentially in either order. Preferred alkyl chains are 9–24 carbons, more preferably 9–14. Suitable saccharides include monosaccharides, oligosaccharides, and polysaccharides, with glucose, maltose, maltotriose, maltotetraose, sucrose, and trehalose named, and maltose, sucrose, and glucose preferred. A preferred surfactant has an HLB of 10–20, more preferably 11–15. A composition is described comprising (a) the alkyl glycoside at 0.01%–1.0% concentration and (b) insulin or glucagon. Candidate compounds include peptides, polypeptides, proteins, peptide hormones (insulin, calcitonin, enkephalins, glucagon), hypoglycemic agents (tolbutamide, glyburide), and poorly enterally absorbed agents such as griseofulvin.
What the excerpt does not establish: It does not provide claim text, examples, experimental data, or a full specification. It reports classifications and legal-status metadata as assumptions, not legal conclusions. It does not establish validity, enforceability, claim scope, or the accuracy of assignee/status listings. It does not show the complete disclosure of the patent.
Source: https://patents.google.com/patent/[US5661130](/patent/US5661130)/en
Generated 10/1/2026, 9:42:44 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 5661130. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.